U.S. Cell And Gene Therapy Clinical Trial Services Market Size, Share & Trends Analysis Report By Service (Site Identification, Patient Recruitment), By Phase (Phase I, Phase II), By Therapeutic Areas, By Therapy Type, And Segment) - Industry Analysis, Sh

The U.S. cell and gene therapy clinical trial services market size was valued at USD 7.19 billion in 2023 and is projected to surpass around USD 56.53 billion by 2033, registering a CAGR of 22.9% over the forecast period of 2024 to 2033.

Key Takeaways:

The regulatory services segment held the largest revenue share of 21.34% in 2023.
The supply and logistic services segment is anticipated to register a considerable CAGR of 23.3% over the forecast period.
The phase II segment held the largest revenue share of 48.19% in 2023.
The phase I segment is anticipated to register the fastest CAGR of 23.2% during the forecast period.
The oncology segment held the largest revenue share of 56.9% in 2023.
The central nervous system (CNS) disorders segment is anticipated to register the fastest CAGR of 24.7% during the forecast period.
The cell therapy segment held the largest revenue share of 40.65% in 2023.
The gene-modified cell therapy segment is expected to register the fastest CAGR of 23.6% during the forecast period.

U.S. Cell And Gene Therapy Clinical Trial Services Market Overview
The U.S. Cell and Gene Therapy (CGT) Clinical Trial Services Market represents a dynamic and rapidly expanding segment of the clinical research ecosystem. Fueled by breakthroughs in personalized medicine, regenerative therapy, and immuno-oncology, the demand for comprehensive and specialized services to support cell and gene therapy clinical trials has soared in recent years.
These therapies hold transformative potential in treating complex and previously untreatable diseases, including rare genetic disorders, cancers, neurodegenerative diseases, and cardiovascular conditions. However, the complexity of CGT trials—ranging from logistics of living cell materials to unique regulatory pathways and patient recruitment hurdles—requires specialized clinical trial support.
The U.S. remains the epicenter of global CGT research, backed by a strong pharmaceutical and biotech pipeline, top-tier academic medical centers, and progressive regulatory frameworks. The FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation has further accelerated approvals and incentivized innovation.
The clinical trial services market in this domain spans from site identification and patient recruitment to laboratory analytics, logistics, and manufacturing support. Contract research organizations (CROs), biotech sponsors, academic institutions, and clinical trial networks form the key players within this evolving ecosystem.
U.S. Cell And Gene Therapy Clinical Trial Services Market Report Scope

Report Attribute
Details

Market Size in 2024
USD 8.84 Billion

Market Size by 2033
USD 56.53 Billion

Growth Rate From 2024 to 2033
CAGR of 22.9%

Base Year
2023

Forecast Period
2024 to 2033

Segments Covered
Service, phase, therapeutic areas, therapy type

Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)

Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Key Companies Profiled
Novartis AG; Takeda Pharmaceutical Company Limited.; Gilead Sciences, Inc.; Amgen Inc.; bluebird bio, Inc.; Regeneron Pharmaceuticals Inc.; CRISPR Therapeutics; Pfizer; Biocair; Modality Solutions LLC; BioLife Solutions, Inc.; Marken; Yourway; Almac Group; Catalent, Inc; Quick International Courier (QuickStat (Kuehne + Nagel Company)

Key Driver: Expanding CGT Pipeline and Accelerated Regulatory Designations
A critical driver of the U.S. CGT clinical trial services market is the expansion of the therapeutic pipeline and regulatory incentives accelerating trial timelines. According to FDA data, the number of investigational new drug (IND) applications for CGT products has risen sharply, with over 2,000 active CGT clinical trials globally, many of which are U.S.-based.
Designations such as Orphan Drug, Breakthrough Therapy, Fast Track, and RMAT status have significantly reduced development timelines for eligible therapies. This creates an urgent demand for agile and specialized clinical trial support, particularly in site activation, patient identification, regulatory navigation, and manufacturing coordination.
Examples include the rise of CAR-T cell therapy trials for hematological malignancies, where patient enrollment, cell extraction, and lab processing must occur within tight windows, supported by end-to-end clinical trial services. The momentum from biotech funding, venture capital investment, and pharma partnerships sustains this driver over the long term.
Key Restraint: Complex Logistics and High Operational Costs
The most significant restraint limiting wider scalability of CGT clinical trials is the high cost and complexity of operational logistics. Unlike traditional drugs, cell and gene therapies often involve autologous treatments (where cells are derived from the patient), cryopreserved materials, or genetically modified vectors, all of which require stringent handling and regulatory compliance.
Cold chain logistics, time-sensitive transportation, coordination between sites and manufacturing units, and the need for GMP-compliant facilities drive up trial costs significantly. Moreover, the scarcity of eligible patients, especially in rare disease trials, further complicates the process of patient recruitment and trial site selection.
These challenges require substantial investment in infrastructure, supply chain integration, and specialized personnel barriers that smaller biotech firms often struggle to overcome, leading to reliance on experienced CROs and service vendors.
Market Opportunity: Rise of Decentralized and Technology-driven CGT Trials
A key opportunity lies in the emergence of decentralized, hybrid, and digitally enabled clinical trial models, particularly suited for rare disease and geographically dispersed patient populations. Given the logistical burdens of site visits and the fragile health of CGT trial participants, the industry is embracing solutions that allow remote monitoring, e-consent, virtual site support, and wearable data collection.
Additionally, AI-driven platforms are being employed for patient identification, protocol design, and site optimization, helping accelerate trial timelines and improve precision in candidate selection. Companies offering integrated solutions that combine logistics with digital patient engagement and real-world data capture are well-positioned to benefit from this evolution.
Technologies such as blockchain for chain-of-custody tracking, machine learning in biomarker analysis, and cloud-based trial management systems are actively transforming the landscape of CGT clinical trials in the U.S.
U.S. Cell And Gene Therapy Clinical Trial Services Market By Service Insights
Laboratory Services Dominate the Market
Laboratory services constitute the largest segment in the CGT clinical trial services market. These services include biomarker testing, genomic analysis, pharmacokinetics (PK), and pharmacodynamics (PD) profiling, which are essential to CGT development.
The personalized nature of cell and gene therapies demands deep analytical support ranging frompatient-specific genotyping to viral vector characterization and potency assays. Many trials require centralized labs equipped to handle biological materials under GxP standards, making this a high-value service segment.
Supply and Logistics Services are the Fastest-growing
Supply and logistic services are the fastest-growing due to the unique handling requirements of CGT materials. Sub-segments such as cryogenic transportation, comparator sourcing, packaging, and real-time tracking systems have seen rapid investment.
Manufacturing services particularly for viral vectors and cell processing are often integrated with logistics, offering end-to-end chain-of-identity and chain-of-custody assurance. With the rising volume of CGT trials, sponsors increasingly outsource these specialized logistics to CROs or CDMOs offering dedicated CGT platforms.
U.S. Cell And Gene Therapy Clinical Trial Services Market By Phase Insights
Phase II Trials Dominate the Market
Phase II trials dominate the CGT clinical landscape in the U.S., reflecting the growing maturity of the pipeline. This phase is critical for dose finding, safety validation, and preliminary efficacy, especially in oncology and rare disease indications.
Given the small, carefully selected patient populations and the need for biomarker-based monitoring, Phase II trials demand specialized trial coordination, site engagement, and regulatory navigation.
Phase I is the Fastest-growing Segment
Phase I trials are growing fastest, driven by the influx of new CGT IND filings and first-in-human studies. These trials are increasingly conducted at academic medical centers or early-phase research hospitals with experience in novel biologicals and stringent safety protocols.
CROs are developing phase-specific service offerings, including healthy volunteer recruitment, specialized toxicology labs, and cell processing units embedded within trial sites.
U.S. Cell And Gene Therapy Clinical Trial Services Market By Therapeutic Areas Insights
Oncology Dominates the Market
Oncology is the dominant therapeutic area for CGT clinical trials, with a heavy focus on CAR-T, TCR-T, and gene editing therapies for hematologic and solid tumors. Services such as tumor antigen analysis, patient lymphocyte collection, and adaptive trial designs are essential in this segment.
The FDA has already approved several oncology-focused CGTs, including Yescarta and Kymriah, setting the precedent for continued growth and investment in cancer-focused trials. Many large and mid-sized CROs have dedicated oncology trial units tailored to gene and cell therapies.
CNS Disorders Are the Fastest-growing Therapeutic Area
Central Nervous System (CNS) disorders, including spinal muscular atrophy (SMA), ALS, and Parkinson’s disease, represent the fastest-growing area for CGT trials. Many of these conditions are monogenic, making them ideal candidates for gene therapy approaches.
Service providers must navigate challenges such as neurological biomarker development, patient retention, and long-term safety tracking, which are complex and expensive but also critical for therapeutic validation.
U.S. Cell And Gene Therapy Clinical Trial Services Market By Therapy Type Insights
Gene-modified Cell Therapy (CAR-T) Dominates the Market
Gene-modified cell therapies, particularly CAR-T cell therapies, dominate the U.S. clinical trial services market. These therapies require extensive patient-specific cell collection, ex vivo modification, and reinfusion protocols, demanding precise trial coordination, chain-of-identity, and regulatory compliance.
CROs providing CAR-T trial support must integrate manufacturing logistics, immunophenotyping labs, patient monitoring tools, and pharmacovigilance systems into one seamless workflow. Leading cancer centers across the U.S. are central hubs for such trials.

Gene Therapy is the Fastest-growing Subsegment
Gene therapy trials especially those utilizing AAV or lentiviral vectors—are growing rapidly, driven by approvals like Zolgensma and ongoing studies in hemophilia, retinal disease, and inherited metabolic disorders.
These therapies are one-time interventions requiring long-term follow-up services, real-world evidence collection, and post-marketing surveillance, providing long-term growth opportunities for clinical trial service providers.
Country-level Analysis
The U.S. is the global leader in CGT clinical trials, accounting for over 50% of global CGT trial activity, supported by regulatory innovation, venture capital funding, and robust infrastructure. The FDA’s Office of Tissues and Advanced Therapies (OTAT) facilitates fast-track reviews, encouraging innovation.
Leading academic centers like MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and University of Pennsylvania serve as CGT trial hubs, offering specialized protocols, GMP cell labs, and translational research support. Meanwhile, CROs are expanding CGT-specific services, often through M&A or partnerships.
In addition, private biotechs and large pharmas are outsourcing more to trial service firms with CGT experience, fostering an ecosystem that supports efficient trial conduct from IND filing through Phase IV.
U.S. Cell And Gene Therapy Clinical Trial Services Market Key Companies & Share Insights
The key players focus on expanding their facilities, product/service launches, collaborations, partnerships, and mergers and acquisitions. These are the key strategic initiatives influencing the industry dynamics. For instance, in January 2022, AmerisourceBergen and TrakCel launched the integrated platform to enhance access to prescribed cell & gene therapies, delivering complete visibility during the treatment. The two platforms are TrakCel’s advanced therapy orchestration platform, OCELLOS, and Fusion, a customer relationship management & patient support platform. Some prominent players in the U.S. cell and gene therapy clinical trial services market (Amalgamation of service providers by sponsor companies and logistic providers) are:
Key Cell And Gene Therapy (CGT) Clinical Trial Sponsors Companies:

Novartis AG
Takeda Pharmaceutical Company Limited.
Gilead Sciences, Inc
Amgen Inc.
bluebird bio, Inc.
Regeneron Pharmaceuticals Inc.
CRISPR Therapeutic
Pfizer

Key Cell And Gene Therapy (CGT) Supply & Logistic Providers Companies:

Biocair
Modality Solutions LLC
BioLife Solutions, Inc.
Marken
Yourway
Almac Group
Catalent, Inc
Quick International Courier (QuickStat (Kuehne + Nagel Company)

Recent Developments

April 2025 – Parexel announced the opening of a new CGT-focused clinical trial unit in Boston to support early-phase oncology trials.

March 2025 – IQVIA launched an AI-powered platform for CGT patient recruitment using genomic databases and social listening tools.

February 2025 – ICON plc completed a partnership with a leading biomanufacturing firm to offer integrated CGT trial and manufacturing support.

January 2025 – Medpace expanded its Cincinnati-based facility to include dedicated cold chain and CGT storage capabilities.

December 2024 – PPD (Thermo Fisher Scientific) reported a 35% increase in CGT trial volume year-over-year, fueled by rare disease sponsors and orphan drug studies.

U.S. Cell And Gene Therapy Clinical Trial Services Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Cell And Gene Therapy Clinical Trial Services market.
By Service

Site Identification
Patient Recruitment
Laboratory Services
Regulatory Services
Supply And Logistic Services

Logistics & Distribution
Storage & Retention
Packaging, Labeling, And Blinding
Manufacturing
Comparator Sourcing
Regulatory and customs support
Other Services

Others

By Phase

Phase I
Phase II
Phase III
Phase IV

By Therapeutic Areas

Oncology
Central Nervous System (CNS) Disorders
Cardiovascular Diseases
Infectious Diseases
Musculoskeletal
Others

By Therapy Type

Gene Therapy
Gene-modified Cell Therapy

CAR T-cell therapies
CAR-NK Cell Therapy
TCR-T Cell Therapy
Others

Cell Therapy